The most common clinical toxicity of VIRAMUNE is rash, with VIRAMUNE attributable rash occurring in 13.6% of patients in combination regimens in controlled studies.
VIRAMUNE- seoseline lööve tekib kombineeritud ravi korral kontrollrühmaga uuringutes 13, 6% - l patsientidest